Medscape

FDA OKs First-in-Class Antipsychotic for Schizophrenia

The US Food and Drug Administration (FDA) has approved Cobenfy (Bristol Myers Squibb), a first-in-class antipsychotic approved for schizophrenia. The drug targets cholinergic receptors as opposed to ...
Miami University

B09 - Effect of Cholinergic Mu-Opioid receptor deletion on locomotor sensitization in CMOR mice

Mentor: Anna Radke, Ph.D. The mu-opioid receptor (MOR) is a receptor in the endogenous opioid system, which is involved in the sensation of pain as well as reward and addiction. Activation of these ...
Miami University

B61 - The Effects of Cholinergic Mu-Opioid Receptor Modulation on Preference and Reward

Opioid Use Disorder (OUD) is a critical and escalating public health crisis in the United States, affecting approximately 6.1 million Americans aged 12 or older. Opioid Use Disorder (OUD) is a ...
Healio

FDA approves first new class of schizophrenia treatment in more than 30 years

Please provide your email address to receive an email when new articles are posted on . Cobenfy is the first antipsychotic medication to treat schizophrenia by targeting cholinergic receptors. The ...